We are proud to share that Markus Sieger, CEO of Polpharma Group, made his first appearance as President of Medicines for Europe at the Annual Conference held this week.
He emphasized the urgent need to secure the economic sustainability of off-patent medicines – a cornerstone for access and competitiveness in Europe. With major changes underway in EU pharmaceutical policy, he called for decisive action on:
- Ensuring timely market entry post-exclusivity through the #EUPharma review
- Supporting sustainable pricing and reimbursement reforms
- Implementing the #CriticalMedicinesAct with reduced bureaucracy and stronger EU solidarity
- Addressing environmental and regulatory burdens under the Urban Waste Water Treatment Directive
His message was clear: it’s time to push for health policies that truly value off-patent innovation.